Tag Archives: Eli Lilly

Adaptive Trial Design and Combo Drugs Needed in Alzheimer’s

FDA’s head of neurology products told industry execs at the Prix Galien Forum that the agency is open to alternative clinical trial designs in Alzheimer’s disease, and would like to see more combination products in clinical testing.
Posted in Agency Insight, FDA, R&D, Regulatory | Also tagged , | Leave a comment

Diabetes Drug Launch 2012: Tip-tops and Promo-flops

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
Posted in Advertising, E-Media, FDA, Marketing, Meetings, Strategy | Also tagged , , , , | 1 Comment

New Non-Profit Alliance of Big Pharma Firms

By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog | Also tagged , , , , , , , , , | Leave a comment

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, healthcare, IP, leadership, Legal, Market Access, Meetings, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , , , , , , , , , , , | 1 Comment

Lilly's Decentralized Global Launch Strategy

Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
Posted in Global, leadership, Market Access, Strategy | Also tagged | Leave a comment
  • Categories

  • Meta